Navigation Links
Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
Date:5/28/2008

ZATION

Albuferon(R) (albumin-interferon alpha 2b), a novel long-acting form of interferon alpha for the treatment of chronic hepatitis C

At the 900-mcg dose now being studied in Phase 3, Albuferon requires half as many injections as Pegasys (peginterferon alfa-2a). Final Phase 2b results in treatment-naive patients, presented in November 2007 at the Annual Meeting of the American Association for the Study of Liver Diseases, demonstrated that the 900-mcg dose of Albuferon every two weeks provided efficacy comparable to Pegasys, with comparable safety, the potential for less impairment of health-related quality of life on treatment, and significantly fewer working patients reporting missed days of work. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

Recent progress: In April 2008, HGS completed the treatment phase of ACHIEVE 2/3, one of two Phase 3 trials of Albuferon (albinterferon alfa-2b) in combination with ribavirin in treatment-naive patients with chronic hepatitis C. The Company expects to complete the treatment phase of ACHIEVE 1 in July 2008. Data were presented in April 2008 at the Annual Meeting of the European Association for the Study of the Liver, which showed that Albuferon's pharmacodynamic characteristics and ability to maintain effective blood levels for a longer period of time than is seen with other long-acting interferons may make it an effective component of future combination treatment with novel antivirals for the treatment of chronic hepatitis C.

Key milestones leading to a potential launch of Albuferon in 2010:

-- Complete the treatment phase of ACHIEVE 1, the Phase 3 trial in

genotype 1 chronic hepatitis C, in July 2008.

-- First Phase 3 data available before the end of 2008 (from ACHIEVE 2/3,

the trial in genotypes 2 and 3 chronic hepatitis C).

-- All Phase 3 data ava
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
2. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
3. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
6. First Human Implant of New Archus Orthopedics Facet Replacement System
7. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Data Show SuperGens MP-470 is Safe in Humans
10. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
(Date:9/17/2014)... Sept. 17, 2014  NuView Life Sciences, Inc. ... and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ... genomic-based diagnostic biomarker to detect cancers of the ... other future diagnostic-imaging applications. NuView retains all rights ... and in-vitro urine screen applications. Under ...
(Date:9/17/2014)... Sept. 17, 2014 Cardiac Dimensions ® ... from the TITAN II clinical trial of its ... sustained improvements in mitral regurgitation, functional improvement, quality ... safety and efficacy data, which was consistent with ... 13 at the 26 th annual Transcatheter ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... 4, 2011 A team of scientists at Tufts ... single-cell levels designed to detect breast cancer earlier, and ... Innovator Award from the Department of Defense Breast Cancer ... Ph.D. The Innovator Awards provide "individuals who ...
...   Research led by St. Jude Children,s Research Hospital scientists ... that are the workhorses of cells and, in the ... The discovery involves a chemical known as ... proteins have this chemical added to the amino acid ...
Cached Medicine Technology:Fighting Breast Cancer Early, One Cell At A Time 2Fighting Breast Cancer Early, One Cell At A Time 3Molecule Serves as a Key in Some Protein Interactions 2Molecule Serves as a Key in Some Protein Interactions 3
(Date:9/18/2014)... Lewisville, TX (PRWEB) September 18, 2014 ... of independent freestanding emergency rooms in the United States, ... of its new Missouri City-Lakes facility. , “We ... role as facility medical director of our new Missouri ... Director of First Choice Emergency Room. , Dr. ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 The ... solutions, from active, to medium, and even long term ... content for any length of time. This includes media ... machine-produced data. When used together, Nautilus and ASG-Digital Archive ... archive content. , "storageFOUNDRY is pleased to work ...
(Date:9/17/2014)... The global ablation technologies market is estimated to ... 2019. Although mature markets (such as the U.S., Germany, ... ablation technologies market in 2014, the Asia-Pacific region is ... in the next five years.Factors such as increasing government ... hospitals and surgical centers, and the rising focus of ...
(Date:9/17/2014)... September 18, 2014 Dr. Shalev is a ... to Houston to study at the University of Texas, and ... studying she realized her real passion lay in dentistry, and ... from the University of Texas Health Science Center at Houston ... and is a member of The Greater Houston Dental Society, ...
(Date:9/17/2014)... 18, 2014 US medical facilities are ... medical waste in 2014. Due to public safety concerns, ... along with municipal solid waste. An increasing number of ... waste (RMW). This includes disposable items that may be ... materials. As a result of increased regulation, most small ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 3
... Diluted Earnings Per Share of $0.70; Sales Up 25%; Net Earnings ... $65 Million; Operating Cash Flow of $91 Million, ... ) reported results for the third quarter ended September 30,2007 that ... per share (DEPS) were $0.70 compared to $0.56 in,the third quarter ...
... Oct. 25 As of 1:00 p.m. PST,today, ... Miguel,Covenant Village retirement campus in Spring Valley. Emergency ... living,apartments and residents were transported to the campus ... Loma. The residents were evacuated late,Monday night. ...
... new way to treat individuals with cancer that is ... and kill cancer cells while leaving normal cells unharmed. ... study, David Kirn and colleagues at Jennerex Biotherapeutics, San ... with antitumor effects in both mice and rabbits. , ...
... Mich.---The University of Michigan is the lead research institution ... to study the health consequences on victims in disasters. ... Disaster Mental Health Research, includes researchers from U-M, Dartmouth ... and the University of Oklahoma. The center is funded ...
... Realtors testified at the Senate Finance Committee hearing today ... the needs of,its self-employed members. Nearly 30 percent of ... reason - 84 percent of Realtors who do,not have ... that tax incentives for the self-employed and for small,employers, ...
... LANSING, Mich., Oct. 25 American,Physicians Capital, Inc. (APCapital) ... million or $1.21 per diluted common share for the ... 2007, APCapital has generated,net income of $40.1 million, or ... book value per share was $25.61 based on,10,575,799 shares ...
Cached Medicine News:Health News:Roper Industries Announces Record Third Quarter Results 2Health News:Roper Industries Announces Record Third Quarter Results 3Health News:Roper Industries Announces Record Third Quarter Results 4Health News:Roper Industries Announces Record Third Quarter Results 5Health News:Roper Industries Announces Record Third Quarter Results 6Health News:Roper Industries Announces Record Third Quarter Results 7Health News:Roper Industries Announces Record Third Quarter Results 8Health News:Roper Industries Announces Record Third Quarter Results 9Health News:Roper Industries Announces Record Third Quarter Results 10Health News:U-M to lead disaster aftermath research center 2Health News:Nearly 30 Percent of Realtors(R) Lack Health Insurance 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 3Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 4Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 5Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 6Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 7Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 8Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 9Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 10Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 11Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 12Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 13
... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
The new TRC-NW200 Non-Mydriatic Retinal Camera combines Topcons years of experience in retinal imaging with the latest advances in digital and electronic technology....
... is indicated for the treatment of ... as telangiectasia, rosacea, spider angiomas, cherry ... papulosis nigra and keratoses. Patented ... selection of handpieces maximizes versatility, compact ...
... handpieces, used for endophotocoagulation ... with uncompromised laser treatment ... EndoProbe handpieces are compatible ... green (532 nm), OcuLight ...
Medicine Products: